

Review

Effectiveness of cognitive–behavioural therapies of varying complexity in reducing depression in adults: systematic review and network meta-analysis

Ioannis Angelakis, Charlotte Huggett, Patricia Gooding, Maria Panagioti and Alexander Hodkinson

Background

Cognitive–behavioural therapy (CBT) is frequently used as an umbrella term to include a variety of psychological interventions. It remains unclear whether more complex CBT contributes to greater depression reduction.

Aims

To (a) compare the effectiveness of core, complex and ultra-complex CBT against other psychological intervention, medication, treatment-as-usual and no treatment in reducing depression at post-treatment and in the long term and (b) explore important factors that could moderate the effectiveness of these interventions.

Method

MEDLINE, PsycInfo, Embase, Web of Science and the Cochrane Register of Controlled Trials were searched to November 2021. Only randomised controlled trials were eligible for the subsequent network meta-analysis.

Results

We included 107 studies based on 15 248 participants. Core (s.m.d. = -1.14 , 95% credible interval (CrI) -1.72 to -0.55 [m.d. = -8.44]), complex (s.m.d. = -1.24 , 95% CrI -1.85 to -0.64 [m.d. = -9.18]) and ultra-complex CBT (s.m.d. = -1.45 , 95% CrI -1.88 to -1.02 [m.d. = -10.73]) were all significant in reducing depression up to 6 months from treatment onset. The significant benefits of the ultra-complex (s.m.d. = -1.09 , 95% CrI -1.61 to

-0.56 [m.d. = -8.07]) and complex CBT (s.m.d. = -0.73 , 95% CrI -1.36 to -0.11 [m.d. = -5.40]) extended beyond 6 months. Ultra-complex CBT was most effective in individuals presenting comorbid mental health problems and when delivered by non-mental health specialists. Ultra-complex and complex CBT were more effective for people younger than 59 years.

Conclusions

For people without comorbid conditions healthcare and policy organisations should invest in core CBT. For people <59 years of age with comorbid conditions investments should focus on ultra-complex and complex CBT delivered without the help of mental health professionals.

Keywords

Cognitive–behavioural therapy; major depressive disorder; treatment complexity; systematic review; network meta-analysis.

Copyright and usage

© The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Major depressive disorder (MDD) is the most common mental health condition, with more than 264 million people being affected worldwide.¹ It has a negative impact on people's quality of life and is very costly for health and care systems.² Cognitive–behavioural therapy (CBT) is an evidence-based psychological intervention that is widely used for treating MDD. There are large variations in terms of the components delivered as part of CBT protocols. The two main elements of CBT for depression are: (a) behavioural activation aiming to understand the potentially reciprocal relationships between negative mood states and behaviours³ and (b) cognitive restructuring aiming to increase behaviours associated with positive moods and identify, critically evaluate and challenge maladaptive automatic thoughts.⁴ Recent evidence examining the effectiveness of each of these components alone or in combination suggested that they were equally effective in reducing depression in adults compared with treatment as usual or no treatment.⁵

Social skills training⁶ (including non-verbal and communication skills as well as assertiveness training), relaxation techniques⁷ and psychoeducation⁸ may be used to supplement the effectiveness of core CBT. Techniques such as problem-solving skills,⁹ self-management skills¹⁰ and relapse prevention¹¹ may also be used, most likely because patients with depression may present with multiple

comorbidities, including anxieties,¹² cancer¹³ and diabetes.¹⁴ It is standard practice for studies focusing on psychological treatments for depression to use core,¹⁵ complex¹⁶ containing behavioural activation and/or cognitive restructuring with either psychoeducation, skills training modules or relaxation techniques, and/or ultra-complex CBT protocols¹⁷ that include core CBT with at least two or more additional therapeutic components as mentioned above.

To date no study has examined the differential effectiveness of each of these CBT protocols in reducing depression in adult populations. For example, ample is the evidence garnered from several meta-analyses demonstrating the effectiveness of CBT in significantly reducing symptoms of depression in comparison with no intervention or treatment as usual (TAU).^{18–20} Despite this, evidence on differences in the effectiveness as well as scope (e.g. subgroups of people with MDD) of the core and multicomponent CBT protocols at post-treatment and in the long term is lacking. There are also uncertainties whether specific characteristics of participants, intervention, therapists or context can influence the effectiveness of core and multicomponent CBT. Understanding whether multicomponent CBT protocols are more effective than core CBT, for which patient groups and how they should be delivered has important practice and policy implications. These include improved

access for underserved patient groups and reducing healthcare inequalities, time and training requirements for therapists and overall healthcare service delivery costs.

To address this important gap in the literature, this systematic review and network meta-analysis aimed to (a) comparatively assess the effectiveness of core, complex and ultra-complex CBT protocols in reducing symptoms of depression in adults with depression at post-treatment and in the long term and (b) examine moderators of these protocols, including characteristics of participants, interventions, therapists and context.

Method

Eligibility criteria

Studies involving participants aged 17 years and older with depression were eligible. Depression could have been verified through the use of either validated self-report measures or clinical interviews. Studies that recruited participants with comorbid mental health problems such as anxiety were also included. However, studies focusing on COVID-19-related depression were excluded.

We focused on studies involving core CBT protocols using either behavioural activation, or cognitive restructuring or both as the primary treatment components and based on any type of delivery mode, including face-to-face or online individual/group sessions. Studies that incorporated additional cognitive-behavioural therapeutic components to the two core components above, including problem-solving and self-management techniques, relaxation and social skills training, relapse prevention and psychoeducation, were also included, if they were based on behavioural activation and/or cognitive restructuring modules. CBT protocols were grouped into three discrete categories according to the complexity of the included components: core CBT (comprising behavioural activation and cognitive restructuring), complex CBT (core CBT plus one additional component that included psychoeducation or training in particular skills, including social skills training and relaxation techniques) and ultra-complex CBT (core CBT plus two or

more additional components that included problem-solving skills, self-management skills, relaxation techniques, psychoeducation and/or relapse prevention; interventions are defined in Table 1 and therapeutic components of the included studies are described in supplementary Appendix 2, available at <https://doi.org/10.1192/bjp.2022.35>). Studies comparing the effectiveness of the core components of CBT with each other (e.g. behavioural activation versus cognitive restructuring) or comparing the effectiveness of the different formats of delivery of CBT (e.g. face-to-face CBT versus telephone-delivered CBT or remote online CBT) were excluded.

The control groups involved a mixture of individuals on waiting lists, receiving TAU (participants allocated to the 'no treatment' condition were also listed in this category because they are prone to seek treatment while a study is being conducted), or any other psychological or pharmacological treatment.

Primary outcomes were validated self-reported measures of depression at baseline, post-treatment and/or additional follow-up points. Studies that did not report their outcomes regarding depressive symptoms at either baseline or post-treatment and/or provided insufficient data for a meta-analysis were excluded.

We included randomised controlled trials (RCTs) evaluating the effectiveness of CBT protocols. We excluded observational, cross-sectional and qualitative studies. Studies that were not in English were also excluded.

Search methods

We searched the bibliographic databases MEDLINE, PsycInfo, Embase, Web of Science and the Cochrane Register of Controlled Trials from 1 January 1990 to 30 November 2021. Two authors (I. A., C.H.) independently screened the titles/abstracts and the full texts of potentially eligible studies and extracted data. Interrater reliability was high ($\kappa = 0.91$) for title/abstract screening and high ($\kappa = 0.94$) for full-text screening. Disagreements were resolved through discussion. The reference lists of the identified studies and those of previous reviews were examined to ensure that all relevant studies were included. We also contacted experts in the field to enquire about unpublished studies and searched trials registers (ClinicalTrials.gov, ISRCTN, the World Health Organization's International Clinical Trials Registry Platform (ICTRP) and OpenTrials.net) to identify any unpublished or ongoing trials. The full search strategy is available in supplementary Appendix 1.

Data collection and extraction

A data extraction sheet was constructed and pilot tested on six randomly selected papers. Data were extracted on: (a) study/context characteristics: authors, geographic region where the study was conducted and method of measuring depressive symptoms; (b) participant characteristics: age, gender identity and presence of comorbidities; (c) CBT characteristics: number of and/or components of CBT used, number of sessions, length of sessions and delivery format; (d) therapist characteristics: background in mental health services and supervision received; (e) active control/control group characteristics: no treatment, waiting list, TAU, or other psychological and/or pharmacological interventions; and (f) outcomes: measures of depression.

We also extracted arm-level data including information about sample sizes, means and standard deviations for both intervention and control conditions at baseline (when reported), post-treatment and follow-up. Standardised mean difference (s.m.d.) effects and the corresponding standard error were computed using the Comprehensive Meta-Analysis Version 3 (Windows) software.²¹

Table 1 Description of intervention models

Intervention model	Description
Core CBT	Cognitive-behavioural therapy based on cognitive restructuring and/or behavioural activation
Complex CBT	Cognitive-behavioural therapy based on cognitive restructuring and/or behavioural activation plus one additional therapeutic component; this component included either psychoeducation or training on skills, including social and relaxation skills
Ultra-complex CBT	Cognitive-behavioural therapy based on cognitive restructuring and/or behavioural activation plus two or more additional therapeutic components; these components included problem-solving skills, self-management skills, relaxation training, psychoeducation and/or relapse prevention
Other psychological treatment	Psychological interventions based on mindfulness, relationships (couple therapy), systemic interventions (family-based programmes), psychoeducation alone and counselling
Medication	Interventions based on the prescription of medicines (fluoxetine, sertraline)
Treatment as usual (TAU)	Standard care, including assessment, advice, social support; and/or allocation to 'no treatment' groups
Waiting list	Groups of patients waiting to receive treatment

Quality assessment and risk of bias

The quality of the RCTs was assessed by two independent raters (I.A., C.H.) using the Cochrane Risk of Bias 2 (RoB 2.0) tool.²² Additionally, we applied the confidence in network meta-analysis (CINeMA) framework²³ to assess the certainty of evidence covering the six key domains: within-study bias, reporting bias, indirectness, imprecision, heterogeneity and incoherence.

Data synthesis

We first did the pairwise meta-analyses using DerSimonian–Laird random effects. We calculated standardised mean differences using Hedges' *g* and interpreted them according to Cohen's criteria.^{24,25} A negative s.m.d. indicated that the reduction in depression scores was in favour of the CBT protocols. We presented pooled effect results with 95% confidence intervals and used forest plots with I^2 (with test-based 95% confidence intervals) to display statistical heterogeneity.²⁶ Because the s.m.d. is based on standardised means and not a specific scale (i.e. is unit-less), we back-transformed the s.m.d. pooled effects to the mean difference using the method explained in the Cochrane Handbook.²⁷

We then synthesised the study effect sizes by using a network meta-analysis which allowed for the simultaneous evaluation of our seven interventions while preserving the within-study randomisation.²⁸ To ensure transitivity within the network, we compared the distribution of the clinical variables (i.e. age, gender and baseline depression score) by grouping the different CBT protocols, other psychological treatments, medication, TAU and 'no treatment' groups into nodes.²⁹ A Bayesian random-effects network meta-analysis model was used with a normal likelihood for the post-treatment outcome analysis. The 95% credible interval (CrI) displayed uncertainty in the posterior effects and multivariate distributions were used to account for the correlations induced by multigroup studies. We considered the I^2 statistic and the (heterogeneity) variance in the random effects distribution (τ^2) to measure the extent of the influence of variability across and within studies on treatment effects. The surface under the cumulative ranking curve (SUCRA)³⁰ was used to rank the treatments' performance, as well as the P-score, a frequentist analogue to SUCRA. We statistically evaluated consistency by separating out direct evidence from indirect evidence using node splitting.³¹ Cochrane's *Q* statistic was used to calculate consistency throughout the entire network.³² The CINeMA judgements were included in the league table of results and forest plots.

Meta-regression analyses were conducted on the post-treatment outcomes only because the exact same studies were included in the long-term analysis, meaning that the variables would be the same. The study and participant characteristics that were included in the analyses were: geographical continent where the study was conducted (1, North and South America; 2, Europe; 3, Africa; 4, Asia; 5, Oceania); socioeconomic status (high versus low); age (≤ 30 years, 31–59 years, ≥ 60 years); gender (males versus females); diagnosis (self-reported versus formal/interview); recruitment (community versus in-patient); and comorbidities (none, mental health, physical). The intervention characteristics included intensity of the treatment (low: 1–8 sessions; medium: 9–15 sessions; high: 16+ sessions); delivery by a mental health specialist (yes, no, not applicable); CBT format (individual face-to-face/telephone, face-to-face group, online/face-to-face self-help with some therapist support, online self-help with no therapist support); and measure of depression used (Patient Health Questionnaire (PHQ-9); Beck Depression Inventory (BDI); Hamilton Rating Scale for Depression (HRSD); Center for Epidemiology Depression (CES-D); other). The influence of the quality appraisal scores (low, medium, high) on the effects of different CBT protocols in reducing depressive symptoms was also

examined. We assessed goodness of fit for each model by comparing total residual deviance and deviance information criterion.

The models of the post-treatment outcome analysis were fitted in OpenBUGS (version 3.2.3 for Windows)³³ using uninformative prior distributions for the treatment effects and a minimally informative prior distribution for common heterogeneity standard deviation. Uninformative priors (that is, $N(0,1000)$) were assumed for all meta-regression coefficients. Model convergence was established by visual inspection of three Monte Carlo Markov chains after considering the Brooks–Gelman–Rubin diagnostic. Statistical evaluation of inconsistency and production of network graphs and results figures was done using the 'netmeta' package in R version 4.0.5 (Windows) (R Foundation for Statistical Computing).³⁴ Network meta-analysis of the post-treatment outcome was duplicated in a frequentist environment by using the same package in R.

A time adjusted analysis of the network involving the outcome data from the 54 studies replacing the post-treatment data was done at 26 weeks to assess the long-term effectiveness of the interventions. This analysis was done using the frequentist approach in 'netmeta'. Our definition of the long-term effects of CBT interventions as being 6 months (26 weeks) follows the assumptions made from a previous study that this was when the effects appeared to start to wane.¹⁸

To examine the presence of bias due to small-study effects, we used a comparison-adjusted network funnel plot to visually scrutinise the criterion of symmetry.³⁵ We also statistically compared the effect sizes between short- and long-term outcomes (i.e. < 26 weeks versus ≥ 26 weeks) using the ratio of means (ROM) formula.³⁶ All statistical codes used to perform the network models are available in supplementary Appendix 13.

This study was conducted in accordance with the Cochrane Handbook²² and was registered with PROSPERO (registration number CRD42021237846). Reporting was consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for network meta-analysis.³⁷ See supplementary Appendix 14 for the completed checklist.

Patient and public involvement

This study was guided by two patients with lived experience of depression who had received CBT in the past. They contributed to the refinement of the research questions, classifications of the treatment protocols and interpretation of the results. They will also support the dissemination of the findings of the study.

Results

A total of 3975 articles were retrieved. After full-text screening of 511 studies, 107 RCTs (involving 15 248 participants) met our inclusion criteria (Fig. 1). Of those, 54 (50%) studies (involving 6383 participants) provided follow-up data. Supplementary Appendix 2 lists the included studies, and supplementary Appendix 4 summarises their characteristics.

Descriptive characteristics of studies, population, intervention and outcomes

Combined, 43% ($n = 46$) of the studies were conducted in North and South America, 31.8% ($n = 34$) in Europe and the UK, 11.2% ($n = 12$) in Oceania, 13% ($n = 14$) across Asia, including such countries as China, Japan, Pakistan, Iran and Thailand, and 1% ($n = 1$) in Nigeria, Africa.

The age of the participants ranged between 22.6 and 74.7 years (mean 41.5; s.d. = 13.5) with 5627 (36.3%) of the overall sample identifying as male. Fifty-eight (54.2%) studies diagnosed




Fig. 1 PRISMA 2020 flow diagram for the entire review.

depression using formal diagnoses, whereas the remaining 49 (45.8%) used self-report measures. Of those studies in which participants reported additional physical ($n = 26$; 70.3%) or mental ($n = 11$; 29.7%) health problems, the most common were HIV, cancer, multiple sclerosis, cardiovascular problems and diabetes, whereas anxiety disorders ($n = 8$; 72.7%) were among the most common comorbid mental health problem.

Of the total 127 comparisons included in this review, 67 (52.8%) were based on ultra-complex CBT, 36 (28.3%) on complex CBT and 24 (18.9%) on core CBT protocols. All CBT protocols were compared with multiple comparators including TAU (57; 44.8%), no intervention and/or waiting list conditions (36; 28.3%), another psychological therapy, including interpersonal and psychodynamic psychotherapy (22; 17.3%), and medication alone (13; 10.2%). Regarding the mode of delivery of the psychological interventions, 46 (36.2%) studies used a face-to-face individual format, 40 (31.5%) used group sessions, 37 (29.1%) used an online format with and/or without a therapist's support, 3 (2.4%) used either a face-to-face or online teaching-based format and 1 (0.8%) used self-help. The average number of sessions was 9.8 (s.d. = 4.7), with a mean length of 72.7 min (s.d. = 27.5).

Assessment of risk of bias

The overall bias appraisal revealed that 79 studies (73.8%) showed moderate risk, 16 (15%) studies demonstrated low risk and 12 (11.2%) showed high risk of bias. An area of bias that was potentially problematic was selective reporting bias: 91 (85%) of studies showed moderate or high risk of bias. Results of the full risk of bias assessment are reported in supplementary Appendix 5.

Network meta-analysis for main outcomes

Figure 2 shows the network of eligible comparisons for all core CBT packages for the post-treatment outcomes from the 107 studies. The network of evidence included 7 interventions, 15 248 participants, 90 two-arm studies and 17 multi-arm studies.

Inconsistency analysis

We found evidence of statistical inconsistency through node splitting analysis owing to comparisons of complex CBT ($z = -4.67$, $P < 0.0001$) with no treatment, complex CBT with TAU ($z = 2.94$, $P = 0.003$) and core CBT with no treatment ($z = 2.19$, $P = 0.029$) (supplementary Appendix 6). The inconsistency for complex CBT compared with TAU was due to one study,³⁸ which showed a high overall risk of bias, a large effect size and large standard error. The inconsistency for complex CBT compared with no treatment was owing to one study,³⁹ which revealed high risk of bias because of missing data, concerns due to the unknown randomisation procedure used and the extremely wide confidence interval. Finally, the inconsistency for core CBT compared with no treatment was due to one study,¹⁵ which had a high risk of bias for the randomisation process used and concerns of measurement outcome and outcome reporting bias. Because consistency (transitivity) is a central assumption of network meta-analysis, we removed all three trials, leaving 104 RCTs in the network.

Main outcomes

Figure 2 shows the results of the network meta-analysis for the main outcomes of all eligible trials after performing the inconsistency analysis. All active interventions, including core CBT (s.m.d. = -1.14 , 95% CrI -1.72 to -0.55 [m.d. = -8.44 , 95% CrI -12.73 to -4.07], $n = 6$ studies), complex CBT (s.m.d. = -1.24 , 95% CrI -1.85 to -0.64 [m.d. = -9.18 , 95% CrI -13.69 to -4.74], $n = 9$), ultra-complex CBT (s.m.d. = -1.45 , 95% CrI -1.88 to -1.02 [m.d. = -10.73 , 95% CrI -13.91 to -7.55], $n = 21$), other psychological psychotherapies (s.m.d. = -0.76 , 95% CrI -1.35 to -0.16 [m.d. = -5.62 , 95% CrI -9.99 to -1.18]; $n = 3$), medication (s.m.d. = -0.80 , 95% CrI -1.58 to -0.01 [m.d. = -5.92 , 95% CrI -11.69 to -0.07]; $n = 2$) and TAU (s.m.d. = -0.74 , 95% CrI -1.24 to -0.23 [m.d. = -5.48 , 95% CrI -9.18 to -1.70]; $n = 2$) showed statistically significant benefits compared with no treatment. Large heterogeneity was present in the network meta-analysis, with $I^2 = 91.5\%$ (95% CI 90.3–92.6%) (supplementary Appendix 7).




Fig. 2 Network graph and forest plot of network meta-analysis for main outcomes.

CBT, cognitive-behavioural therapy; TAU, treatment as usual; a, low confidence of evidence; b, moderate confidence of evidence.

These results were consistent when analysed in a frequentist framework. The pairwise meta-analysis results for the main outcomes were also consistent for core and multicomponent CBT when compared with either TAU or no treatment (supplementary Appendix 8).

The SUCRA also supported the network meta-analysis showing the best performing intervention as ultra-complex CBT (SUCRA = 93.9%) followed by complex CBT (SUCRA = 77.7%) (supplementary Appendix 9).

The league table showing the results of the network meta-analysis comparing the effects of all interventions (Fig. 3) showed that both ultra-complex (s.m.d. = -0.71, 95% CrI -1.05 to -0.38 [m.d. = -5.25, 95% CrI -7.77 to -2.81]) and complex CBT protocols (s.m.d. = -0.50, 95% CrI -0.95 to -0.06 [m.d. = -3.70, 95% CrI -7.03 to -0.44]) were the only interventions that maintained a significant effect when compared with TAU. Ultra-complex CBT was also significantly more effective than the use of other psychological treatments (s.m.d. = -0.69, 95% CrI -1.19 to -0.20 [m.d. = -5.11, -8.81 to -1.48]). To ensure the certainty of evidence, we incorporated the CINeMA judgements into Fig. 3. The evidence

according to CINeMA varied from low ($n = 6$ head-to-head comparisons), to moderate ($n = 5$) to high ($n = 7$) confidence overall (supplementary Appendix 10). Funnel plots and Egger's test for assessing asymmetry indicated strong evidence for publication bias ($P < 0.0001$) (supplementary Appendix 11).

Covariate adjusted network at 26 weeks (6 months) including follow-up data

The long-term effectiveness of each active intervention, including various CBT protocols, other psychological treatment, medication and TAU, was assessed in the covariate-adjusted network model for 26 weeks or more use (see Fig. 4 for forest plot and Fig. 5 for league table of comparisons). Ultra-complex CBT (s.m.d. = -1.09, 95% CI -1.61 to -0.56 [m.d. = -8.07, 95% CI -8.58 to -4.14]), complex CBT (s.m.d. = -0.73, 95% CI -1.36 to -0.11 [m.d. = -5.40, 95% CI -10.06 to -0.81]), other psychological treatments (s.m.d. = -0.71, 95% CI -1.37 to -0.04 [m.d. = -5.25, 95% CI -10.14 to -0.30]) and TAU (s.m.d. = -0.48, 95% CI -0.86 to

Ultra Complex-CBT	-0.27 (-1.56 to 1.03)	-0.04 (-1.38 to 1.29)	-0.20 (-1.14 to 0.74)	-0.35 (-0.78 to 0.08)	-0.74 (-1.07 to -0.42)	-1.48 (-2.17 to -0.79)
-0.21 (-0.72 to 0.30) ^d	Complex-CBT	-1.48 (-3.23 to 0.27)	-0.07 (-0.75 to 0.62)	-0.09 (-0.77 to 0.60)	-0.34 (-0.66 to -0.03)	-3.11 (-3.47 to -2.75)
-0.31 (-0.84 to 0.21) ^e	-0.11 (-0.72 to 0.51) ^d	Core-CBT	-0.32 (-1.02 to 0.38)	-0.30 (-0.83 to 0.22)	-0.53 (-0.88 to -0.17)	-0.46 (-0.74 to -0.19)
-0.65 (-1.37 to 0.05) ^c	-0.44 (-1.17 to 0.28) ^d	-0.34 (-1.07 to 0.38) ^e	Medication	0.00 (-1.33 to 1.33)	-0.52 (-1.47 to 0.44)	-
-0.69 (-1.19 to -0.20) ^b	-0.48 (-1.08 to 0.11) ^d	-0.38 (-0.94 to 0.18) ^d	-0.04 (-0.81 to 0.74) ^c	Other psychological treatment	-0.03 (-0.81 to 0.74)	-1.24 (-2.09 to -0.38)
-0.71 (-1.05 to -0.38) ^b	-0.50 (-0.95 to -0.06) ^b	-0.40 (-0.90 to 0.10) ^c	-0.06 (-0.76 to 0.64) ^d	-0.02 (-0.54 to 0.50) ^d	TAU	-
-1.45 (-1.88 to -1.02) ^b	-1.24 (-1.85 to -0.64) ^b	-1.14 (-1.72 to -0.55) ^c	-0.80 (-1.58 to -0.01) ^b	-0.76 (-1.35 to -0.16) ^b	-0.74 (-1.24 to -0.23) ^c	No treatment

Fig. 3 Head-to-head comparisons of all intervention groups for the main outcome network analysis.

The interventions are described in Table 1. CBT, cognitive-behavioural therapy; TAU, treatment as usual. Data are shown as s.m.d. (95% CrI); -, no direct treatment comparisons. Darker blue cells (bottom) show network meta-analysis estimates; lighter blue cells (top) show direct pairwise meta-analysis estimates. The certainty of the evidence (according to the confidence in network meta-analysis (CINeMA) framework) is: a, very low confidence; b, low confidence; c, moderate confidence; d, high confidence; e, very high confidence. Full results from CINeMA are provided in supplementary Appendix 8.




Fig. 4 Network graph and forest plot of network meta-analysis for time-adjusted analysis.

CBT, cognitive-behavioural therapy; TAU, treatment as usual; wks, weeks.

Ultra-complex CBT < 26 wks	-	-	-0.04 (-1.57 to 1.48)	-0.96 (-1.75 to 0.18)	-0.38 (-1.90 to 1.14)	-	-	-	-0.95 (-1.27 to -0.62)	-	-1.32 (-1.68 to -0.95)
-0.08 (-0.54 to 0.39)	Complex CBT < 26 wks	-	-1.48 (-3.38 to 0.41)	0.04 (-0.86 to 0.93)	-0.23 (-1.32 to 0.87)	-	-	-	-0.45 (-0.97 to 0.08)	-	-2.42 (-3.31 to -1.52)
-0.29 (-0.77 to 0.18)	-0.21 (-0.79 to 0.36)	Ultra complex CBT ≥ 26 wks	-	-	-	-0.39 (-1.91 to 1.13)	-0.02 (-1.51 to 1.47)	-0.42 (-0.99 to 0.16)	-0.64 (-1.07 to -0.22)	-	-0.20 (-1.70 to 1.29)
-0.30 (-0.75 to 0.16)	-0.22 (-0.76 to 0.32)	-0.01 (-0.59 to 0.58)	Core CBT < 26 wks	-0.06 (-0.70 to 0.58)	-0.45 (-1.24 to 0.34)	-	-	-	-0.68 (-1.39 to 0.03)	-	-1.00 (-1.75 to -0.26)
-0.35 (-0.82 to 0.13)	-0.27 (-0.80 to 0.27)	-0.05 (-0.67 to 0.56)	-0.05 (-0.53 to 0.43)	Other psy treatment < 26 wks	-0.50 (-2.02 to 1.02)	-	-	-	-1.05 (-2.14 to 0.04)	-	-1.13 (-2.08 to -0.18)
-0.53 (-1.17 to 0.11)	-0.45 (-1.12 to 0.21)	-0.24 (-0.98 to 0.50)	-0.24 (-0.84 to 0.37)	-0.19 (-0.86 to 0.49)	Medication < 26 wks	-	-	-	-0.64 (-2.20 to 0.92)	-	-
-0.68 (-2.27 to 0.91)	-0.60 (-2.22 to 1.02)	-0.39 (-1.91 to 1.13)	-0.38 (-2.01 to 1.24)	-0.33 (-1.97 to 1.30)	-0.15 (-1.83 to 1.54)	Medication ≥ 26 wks	-	-	-	-	-
-0.65 (-1.23 to -0.07)	-0.57 (-1.23 to 0.09)	-0.36 (-0.95 to 0.24)	-0.35 (-1.02 to 0.32)	-0.30 (-1.00 to 0.40)	-0.11 (-0.92 to 0.70)	0.03 (-1.60 to 1.66)	Complex CBT ≥ 26 wks	0.04 (-1.08 to 1.16)	-0.22 (-0.76 to 0.32)	-	-
-0.67 (-1.29 to -0.05)	-0.59 (-1.29 to 0.10)	-0.38 (-0.89 to 0.13)	-0.38 (-1.09 to 0.33)	-0.33 (-1.06 to 0.40)	-0.14 (-0.98 to 0.70)	0.01 (-1.59 to 1.61)	-0.03 (-0.70 to 0.64)	Other psy treatment ≥ 26 wks	-0.38 (-1.26 to 0.51)	-	-
-0.90 (-1.19 to -0.61)	-0.82 (-1.25 to -0.39)	-0.61 (-0.99 to -0.22)	-0.60 (-1.05 to -0.15)	-0.55 (-1.03 to -0.07)	-0.37 (-1.00 to 0.27)	-0.22 (-1.78 to 1.35)	-0.25 (-0.76 to 0.25)	-0.22 (-0.78 to 0.33)	TAU	0.15 (-0.91 to 1.21)	-
-1.03 (-1.93 to -0.13)	-0.95 (-1.91 to 0.01)	-0.74 (-1.70 to -0.22)	-0.73 (-1.70 to 0.23)	-0.68 (-1.67 to 0.30)	-0.50 (-1.56 to 0.57)	-0.35 (-2.14 to 1.44)	-0.38 (-1.40 to 0.63)	-0.36 (-1.39 to 0.68)	-0.13 (-1.01 to 0.75)	Core CBT ≥ 26 wks	0.24 (-1.29 to 1.77)
-1.38 (-1.70 to -1.06)	-1.30 (-1.79 to -0.82)	-1.09 (-1.61 to -0.56)	-1.08 (-1.55 to -0.62)	-1.03 (-1.53 to -0.54)	-0.85 (-1.51 to -0.19)	-0.70 (-2.31 to 0.90)	-0.73 (-1.36 to -0.11)	-0.71 (-1.37 to -0.04)	-0.48 (-0.86 to -0.10)	-0.35 (-1.26 to 0.56)	No treatment

Fig. 5 League table of head-to-head comparisons of all interventions assessed at 26 weeks (6 months) of long-term use.

Cognitive-behavioural therapy (CBT) interventions are ranked in order of P-scores and are as described in Table 1 but with the time adjustment of 26 weeks. wks, weeks; psy, psychological; TAU, treatment as usual. Data are shown as s.m.d. (95% CI); -, no direct evidence available. Darker blue cells (bottom) show network meta-analysis estimates; lighter blue cells (top) show direct pairwise meta-analysis estimates.

-0.10 [m.d. = -3.55, 95% CI -6.36 to -0.74]) maintained significance after 26 weeks post-treatment when compared with no treatment.

Comparisons between short- and long-term outcomes

Our analyses showed that the effect sizes of ultra-complex CBT (ROM = -0.36, 95% CI 0.31 to -1.04), complex CBT (ROM = -0.51, 95% CI 0.36 to -1.38), core CBT (ROM = -0.79, 95% CI -1.87 to 0.29), medication (ROM = -0.10, 95% CI -1.89 to 1.69), other psychological treatments (ROM = -0.05, 95% CI 0.84 to -0.94) and TAU (ROM = -0.26, 95% CI 0.37 to 0.89) when matched and compared between the two time periods (<26 wks versus ≥26 wks) did not significantly differ in terms of reduction in depression scores.

Meta-regressions

The results of the meta-regression analyses for all the separate CBT and combined CBT protocols are presented in supplementary Appendix 12. Meta-regressions revealed that individuals presenting comorbid mental health problems could benefit more from ultra-complex CBT (*P*-value ranging between 0.04 and 0.03), and coupled with this, depression reductions were greater when symptoms were assessed with the use of formal interviews (*P* = 0.037). Measuring depression using any scale excluding the PHQ-9,⁴⁰ the BDI,⁴¹ the HRSD⁴² and the CES-D⁴³ contributed to significant reductions in effect sizes (*P* ranging between 0.03 and 0.02) for combined CBT compared with no treatment. Younger patients (≤30 years) appeared to contribute better outcomes for those receiving ultra-complex CBT (*P* ranging between 0.001 and 0.01). There was an indication that participants from lower socioeconomic backgrounds responded better to both ultra-complex (*P* = 0.05) and complex CBT (*P* = 0.03). Furthermore, ultra-complex CBT was more effective when delivered by a non-mental health specialist (e.g. nurse, graduate student, other; *P* = 0.04). Group format did not appear to benefit those receiving core CBT, but these analyses were based on only five studies and should be interpreted with caution. Last, the strength of the analyses was not affected by the overall quality appraisal scores of the studies.

Discussion

Summary of main findings

This network meta-analysis compared the effectiveness of core, complex and ultra-complex CBT protocols in reducing depression among adults at post-treatment and 26-week follow-up. Core, complex and ultra-complex CBT protocols were equally effective in reducing depression at post-treatment when compared with no treatment. However, only the ultra-complex and complex CBT protocols sustained these positive effects beyond 26 weeks when compared with no treatment. Both ultra-complex and complex CBT protocols were effective when compared with TAU post-treatment, but only ultra-complex CBT sustained its significance when compared with other psychological treatments for depression. Individuals presenting with comorbid mental health problems and receiving formal interviews also benefited more from the ultra-complex multicomponent CBT. Furthermore, ultra-complex CBT was more effective when delivered by non-mental health specialists (e.g. nurses). This finding may be explained by the fact that nurses providing ultra-complex CBT may also treat these patients for additional conditions and play the role of the main care co-ordinator for a wider range of health problems. However, additional research is needed to verify this. Age appeared to affect the effectiveness of CBT, with participants younger than 30 and those that were 31–59 years responding better to ultra-complex and complex CBT respectively. Meta-regression analyses also demonstrated that participants of lower socioeconomic status responded better to both ultra-complex and complex CBT. Group therapy did not benefit participants receiving core CBT.

Comparison with similar research

These findings are in accord with the treatment guidelines of the National Institute for Health and Clinical Excellence (NICE) and current meta-analyses suggesting that CBT protocols delivered in any format (e.g. individual, group, telephone, guided self-help) are effective treatments for depression in adults.¹⁹ However, this meta-analysis is unique as it is the first to provide evidence on the effectiveness of core, complex and ultra-complex CBT protocols at post-treatment and long-term. For instance, in a recent

network meta-analysis,¹⁸ 211 of the 331 included trials (64%) were classified as CBT but were defined only as a single intervention. Thus, most of the direct evidence contributing to the network was heavily supported from the CBT intervention and little is known about the effects that additional components might have on the clinical efficacy of CBT. Moreover, behavioural activation, a core CBT component for depression, and problem-solving, which is usually used in conjunction with core CBT protocols, were presented as two distinct interventions that were different from CBT. This categorisation may cause confusion regarding the effective CBT components that should be chosen in practice and for varying patient subgroups. A key finding of our study is that all the CBT protocols independent of complexity are significant in reducing depression at post-treatment, with both ultra-complex and complex CBT protocols remaining most effective in longer term.

Strengths and weaknesses

This network meta-analysis is the first to look at the effects of CBT protocols involving multifaceted components over time and has tried to identify the point at which these effects start to wane. We also increased the methodological rigour of our analyses by applying the CINeMA assessment criteria,²³ and assessed heterogeneity through network meta-regression analyses at post-treatment with the inclusion of 11 variables for exploring patient, intervention and study effects.

Five limitations warrant discussion. First, our searches included studies that were published after January 1990. This decision was made because most of the studies published before this date had scored low in the methodological appraisal exercises of previous reviews.²⁰ Second, although complex multicomponent CBT protocols were more effective when compared with other psychological treatments for depression, these psychological treatments included a large variety of multifaceted components based on mindfulness alone, couple therapy, systemic interventions, psychoeducation and counselling. Future studies should compare those studies using CBT and each of these psychological treatments separately. Third, our analyses did not include any studies involving individuals diagnosed with depression and comorbid personality disorders. Therefore, it should be noted that the effectiveness of the ultra-complex CBT protocols to treat depression in those with additional mental health problems may not be experienced by individuals with comorbid personality disorders.⁴⁴ These individuals may gain the most benefit from an amalgamation of psychological and pharmacological treatments.^{45,46} Fourth, little information was provided regarding the concurrent use of medication in the studies included in this review. To overcome this limitation, a more detailed reporting of concurrent medication use is needed that would allow for meta-regression analyses to better determine its clinical benefits. Fifth, although the therapeutic components of the included studies were evaluated based on the published study manuals or the information as reported in the actual papers, it is still possible that there were differences between these reports and the components used. Therefore, these results should be interpreted with caution.

Implications for clinicians and policy makers

We found that core, complex and ultra-complex CBT protocols were equally effective in reducing symptoms of depression at post-treatment. Our back-transformed estimates showed that all CBT protocols reduced depressive symptoms by up to at least 8.44 points on the BDI scale, which was substantial. Ultra-complex and complex CBT sustained these effects in the long-term and reduced depression by at least 8 and 5 points respectively. In people with mental health comorbidities and hence patients with

more severe depression, the additional clinical benefits of the ultra-complex CBT over core or complex CBT protocols were significant, and ultra-complex CBT might therefore be the preferred option. However, for the rest of people with depression, the decision to recommend core, complex or ultra-complex CBT protocols should be based not only on expected clinical benefits (in the form of reductions in depressive symptoms, because these were equivalent) but also on other factors such as accessibility, staff availability and costs.

Ioannis Angelakis , PhD, National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, Division of Population Health, Health Services Research and Primary Care, University of Manchester, UK; and School of Psychology, University of South Wales, Pontypridd, UK; **Charlotte Huggett**, MSc, Greater Manchester Mental Health NHS Foundation Trust, Manchester Academic Health Science Centre, UK; and Division of Psychology and Mental Health, School of Health Sciences, Manchester Academic Health Science Centre, UK; **Patricia Gooding**, PhD, Division of Psychology and Mental Health, School of Health Sciences, Manchester Academic Health Science Centre, UK; **Maria Panagioti**, PhD, National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, Division of Population Health, Health Services Research and Primary Care, University of Manchester, UK; and National Institute for Health Research School for Primary Care Research, Division of Population Health, Health Services Research and Primary Care, University of Manchester, UK; **Alexander Hodkinson**, PhD, National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre, Division of Population Health, Health Services Research and Primary Care, University of Manchester, UK; and National Institute for Health Research School for Primary Care Research, Division of Population Health, Health Services Research and Primary Care, University of Manchester, UK

Correspondence: Dr Ioannis Angelakis. Email: ioannis.angelakis@southwales.ac.uk

First received 18 Oct 2021, final revision 27 Jan 2022, accepted 16 Feb 2022

Supplementary material

Supplementary material is available online at <http://doi.org/10.1192/bjp.2022.35>.

Data availability

The data that support the findings of this study are available on request from the corresponding author.

Acknowledgement

We thank Matilda Angelaki for her generous support and guidance.

Author contributions

I.A. had the initial research idea, formulated the research questions and designed the study. I.A., C.H. and A.H. searched for published work, selected articles, extracted and analysed data. I.A., A.H. and P.G. drafted the protocol and manuscript. A.H. and M.P. helped with searching for articles and data selection and extraction. A.H., M.P. and I.A. substantially contributed to designing the searches and the statistical analysis plan, writing the manuscript and interpreting the findings. A.H. and I.A. performed the statistical analysis. P.G. and C.H. contributed to the manuscript by providing review comments and edits. All authors have read and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. I.A. is the guarantor.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

None.

References

- 1 World Health Organization. *Depression*. WHO, 2021 (<https://www.who.int/news-room/fact-sheets/detail/depression>).
- 2 Greenberg P, Fournier A, Sisitsky T, Pike C, Kessler R. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). *J Clin Psych* 2015; **76**: 155–62.

- 3 Hawley L, Padesky C, Hollon S, Mancuso E, Laposa J, Brozina K, et al. Cognitive-behavioral therapy for depression using mind over mood: CBT skill use and differential symptom alleviation. *Behav Ther* 2016; **48**: 29–44.
- 4 Sudak DM. Cognitive behavioral therapy for depression. *Psychiatr Clin North Am* 2012; **35**: 99–110.
- 5 Ciharova M, Furukawa TA, Efthimiou O, Karyotaki E, Miguel C, Noma H, et al. Cognitive restructuring, behavioral activation and cognitive-behavioral therapy in the treatment of adult depression: a network meta-analysis. *J Consult Clin Psychol* 2021; **89**: 563–74.
- 6 Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, et al. A component analysis of cognitive-behavioral treatment for depression. *J Consult Clin Psychol* 1996; **64**: 295–304.
- 7 Jorm A, Morgan A, Hetrick S. Relaxation for depression. *Cochrane Database Syst Rev* 2008; **4**: CD007142.
- 8 Tursi MF, Cv B, Camacho FR, Tofoli SM, Juruena MF. Effectiveness of psychoeducation for depression: a systematic review. *Aust N Z J Psychiatry* 2013; **47**: 1019–31.
- 9 Bell AC, D'Zurilla TJ. Problem-solving therapy for depression: a meta-analysis. *Clin Psychol Rev* 2009; **29**: 348–53.
- 10 Houle J, Gascon-Depatie M, Bélanger-Dumontier G, Cardinal C. Depression self-management support: a systematic review. *Patient Educ Couns* 2013; **91**: 271–9.
- 11 Gortner ET, Gollan JK, Dobson KS, Jacobson NS. Cognitive-behavioral treatment for depression: relapse prevention. *J Consult Clin Psychol* 1998; **66**: 377–84.
- 12 Cummings CM, Caporino NE, Kendall PC. Comorbidity of anxiety and depression in children and adolescents: 20 years after. *Psychol Bull* 2014; **140**: 816–45.
- 13 Chochinov HM. Depression in cancer patients. *Lancet Oncol* 2001; **2**: 499–505.
- 14 Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. *J Affect Disord* 2012; **142**(suppl): S8–21.
- 15 Collins S, Byrne M, Hawe J, O'Reilly G. Evaluation of a computerized cognitive behavioural therapy programme, MindWise (2.0), for adults with mild-to-moderate depression and anxiety. *Br J Clin Psychol* 2018; **57**: 255–69.
- 16 Clarke G, Reid E, Eubanks D, O'Connor E, DeBar LL, Kelleher C, et al. Overcoming Depression on the Internet (ODIN): a randomized controlled trial of an internet depression skills intervention program. *J Med Internet Res* 2002; **4** (3): E14.
- 17 Leuzinger-Bohleber M, Hautzinger M, Fiedler G, Keller W, Bahrke U, Kallenbach L, et al. Outcome of psychoanalytic and cognitive-behavioural long-term therapy with chronically depressed patients: a controlled trial with preferential and randomized allocation. *Can J Psychiatry* 2019; **64**: 47–58.
- 18 Cuijpers P, Quero S, Noma H, Ciharova M, Miguel C, Karyotaki E, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. *World Psychiatry* 2021; **20**: 283–93.
- 19 Cuijpers N, Noma H, Karyotaki E, Cipriani A, Furukawa TA. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. *JAMA Psychiatry* 2019; **76**: 700–7.
- 20 Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. *Can J Psychiatry* 2013; **58**: 376–85.
- 21 Borenstein M, Hedges L, Higgins J, Rothstein H. *Comprehensive Meta-Analysis Software: Version 3*. Biostat, 2013 (<https://www.meta-analysis.com>).
- 22 Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0*. Cochrane Collaboration, 2001.
- 23 Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med* 2020; **17**(4): e1003082.
- 24 Hedges L. Distribution theory for Glass's estimator of effect size and related estimators. *J Educ Behav Stat* 1981; **6**: 107–28.
- 25 Durlak JA. How to select, calculate, and interpret effect sizes. *J Pediatr Psychol* 2009; **34**: 917–28.
- 26 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557–60.
- 27 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Re-expressing s.m.d.s using a familiar instrument. In *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0*. Cochrane Collaboration, 2001 (https://handbook-5-1.cochrane.org/chapter_12/12_6_4_re-expressing_smds_using_a_familiar_instrument.htm).
- 28 Dias S, Welton NJ, Sutton AJ, et al. *NICE DSU Technical Support Document 2: Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials*. National Institute for Health and Care Excellence, 2014.
- 29 Bafeta A, Trinquart L, Seror R, Ravaud P. Reporting of results from network meta-analyses: methodological systematic review. *BMJ* 2014; **348**: g1741.
- 30 Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011; **64**: 163–71.
- 31 Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 2012; **3**: 98–110.
- 32 Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. *BMC Med Res Methodol* 2013; **13**: 35.
- 33 MRC Biostatistics Unit. *The BUGS Project*. University of Cambridge, 2022 (<https://www.mrc-bsu.cam.ac.uk/software/bugs/>).
- 34 Rücker G, Krahn U, König J, Efthimiou O, Davies A, Papakonstantinou T, et al. Package "netmeta": Network Meta-Analysis Using Frequentist Methods (Version 2.1-0). CRAN, 2022 (<https://cran.r-project.org/web/packages/netmeta/netmeta.pdf>).
- 35 Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Research Synthesis Methods* 2012; **3**: 161–76.
- 36 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003; **326**: 219.
- 37 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; **162**: 777–84.
- 38 Bowers W, Stuart S, Macfarlane R, Gorman L. Use of computer-administered cognitive-behavior therapy with depressed inpatients. *Depression* 1993; **1**: 294–9.
- 39 Hegerl U, Hautzinger M, Mergl R, Kohnen R, Schütze M, Scheunemann W, et al. Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm. *Int J Neuropsychopharmacol* 2010; **13**: 31–44.
- 40 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; **16**: 606–13.
- 41 Beck AT, Steer RA, Brown GK. *Manual for the Beck Depression Inventory-II*. Psychological Corporation, 1996.
- 42 Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; **23**: 56–62.
- 43 Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. *Psychol Aging* 1997; **12**: 277–87.
- 44 Goddard E, Wingrove J, Moran P. The impact of comorbid personality difficulties on response to IAPT treatment for depression and anxiety. *Behav Res Ther* 2015; **73**: 1–7.
- 45 Driessen E, Hollon SD. Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators. *Psychiatr Clin North Am* 2010; **33**: 537–55.
- 46 Matusiewicz AK, Hopwood CJ, Banducci AN, Lejuez CW. The effectiveness of cognitive behavioral therapy for personality disorders. *Psychiatr Clin North Am* 2010; **33**: 657–85.

